Citation

Planken S., Behenna D., Nair S., Johnson T., Nagata A., Almaden C., Bailey S., Ballard T., Bernier L., Cheng H., Cho-Schultz S., Dalvie D., Deal J., Dinh D., Edwards M., Ferre R., Gajiwala K., Hemkens M., Kania R., Kath J., Matthews J., Murray B., Niessen S., Orr S., Pairish M., Sach N., Shen H., Shi M., Solowiej J., Tran K., Tseng E., Vicini P., Wang Y., Weinrich S., Zhou R., Zientek M., Liu L., Luo Y., Xin S., Zhang C., Lafontaine J.: Discovery of <i>N</i>-((3<i>R</i>,4<i>R</i>)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1<i>H</i>-pyrazol-4-yl)amino)-9-methyl-9<i>H</i>-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR. Journal of Medicinal Chemistry, Volume 60 (7), 2017

Authors

Simon Planken, Douglas C. Behenna, Sajiv K. Nair, Theodore O. Johnson, Asako Nagata, Chau Almaden, Simon Bailey, T. Eric Ballard, Louise Bernier, Hengmiao Cheng, Sujin Cho-Schultz, Deepak Dalvie, Judith G. Deal, Dac M. Dinh, Martin P. Edwards, Rose Ann Ferre, Ketan S. Gajiwala, Michelle Hemkens, Robert S. Kania, John C. Kath, Jean Matthews, Brion W. Murray, Sherry Niessen, Suvi T. M. Orr, Mason Pairish, Neal W. Sach, Hong Shen, Manli Shi, James Solowiej, Khanh Tran, Elaine Tseng, Paolo Vicini, Yuli Wang, Scott L. Weinrich, Ru Zhou, Michael Zientek, Longqing Liu, Yiqin Luo, Shuibo Xin, Chengyi Zhang, Jennifer Lafontaine

Journal

Journal of Medicinal Chemistry

Year

2017

DOI

10.1021/acs.jmedchem.6b01894

Machine-readable

REST APIRDF